MTOR and neoplasm: The data presented here on RIF-1 and B16/BL6 tumours confirm these observations for the allosteric mTOR inhibitor everolimus, providing further evidence that ΔT1 reflects the number of remaining proliferating tumour cells following successful chemotherapy.